<a href="https://www.fiercebiotech.com/biotech/ligand-tries-disembark-part-viking-pact-alleging-contract-breach" hreflang="en">Ligand tries to disembark from part of Viking pact, alleging contract breach</a>
Ligand Pharmaceuticals is attempting to terminate its collaboration with Viking Therapeutics over alleged breaches of their licensing agreement related to two TRβ programs, VK0214 and VK2809, which have shown promise in clinical trials. Viking disputes Ligand's claims and the companies are currently in a legal conflict regarding the future of these therapies.
The key insight for a professional interested in healthtech and biotech is the strategic implication of Ligand's attempt to terminate the TRβ program with Viking due to alleged contract breaches. This development underscores the critical importance of maintaining clear and enforceable licensing agreements in biotech collaborations. For those tracking investment opportunities or partnership strategies, this dispute highlights the potential risks and legal complexities involved in drug development partnerships, particularly when milestone payments and future sales royalties are at stake.